In summary, our findings demonstrate that circulating interleukins—particularly IL-1RA, IL-6, IL-8, IL-10, and IL-17A—hold substantial promise as early diagnostic biomarkers for NSCLC. This evidence concerns the gene IL6 and non-small cell lung carcinoma.